|
Synonyms: BIIB-067 | BIIB067 | Qalsody®
tofersen is an approved drug (FDA (2023), EMA (2024))
Compound class:
Nucleic acid
Comment: Tofersen (BIIB067) is an antisense oligonucleotide that disrupts translation of superoxide dismutase 1 (SOD1). Tofersen was designed to treat cases of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) that are associated with expression of mutated SOD1. In fact tofersen is mutation agnostic, and disrupts expression of normal and mutated, toxic forms of the SOD1 protein. SOD1-ALS/MND accounts for ~2% of all cases.
|
| No information available. |
Summary of Clinical Use ![]() |
| Tofersen (Qalsody®) is approved to treat SOD1-ALS/MND. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02623699 | An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) | Phase 3 Interventional | Biogen | 1 | |
| NCT03070119 | Long-Term Evaluation of BIIB067 (Tofersen) | Phase 3 Interventional | Biogen | 1 | |